In summary, we have identified a sensitivity gene expression signature, which can be used to successfully identify cancers with highly activated immune signaling, as well as to accurately predict the sensitivity of GSCs to TAK1 inhibitor HS-276. The gene discussed is MAP3K7; the disease is cancer.